AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7074752 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 30734126 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic fraction group
Number of subjects: 74
Study 30734126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral water group
Number of subjects: 74
Study 30734126 — intervention group
Group type: COMPARATOR
Intervention: Tap water group
Number of subjects: 74
Study 29980770 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-piece IOL
Number of subjects: 0
Study 29980770 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-piece IOL
Number of subjects: 0
Study 29980770 — intervention group
Group type: COMPARATOR
Intervention: Single-piece IOL and Three-piece IOL
Number of subjects: 0
Study 27397118 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound technique (out‐of‐plane orientation and in‐plane guidance)
Number of subjects: 88
Study 27397118 — intervention group
Group type: COMPARATOR
Intervention: Palpation technique (control)
Number of subjects: 88
Study 24977721 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based safety decision aid
Number of subjects: 59
Study 22090454 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised interaction with real patients
Number of subjects: 140
Study 22090454 — intervention group
Group type: EXPERIMENTAL
Intervention: Role playing
Number of subjects: 140
Study 22090454 — intervention group
Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 140
Study 22090454 — intervention group
Group type: COMPARATOR
Intervention: Web-based training
Number of subjects: 140
Study 21090333 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion plus electroacupuncture (M + EA)
Number of subjects: 124
Study 21090333 — intervention group
Group type: COMPARATOR
Intervention: Medication (Antine Capsule, diclofenac sodium, 50 mg, twice daily)
Number of subjects: 124
Study 19192762 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of tramadol in 3‐mL saline
Number of subjects: 8
Study 19192762 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study 15903126 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran (24, 36, 48, or 60 mg twice daily for 12 to 16 days)
Number of subjects: 264
Study 12628948 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BNP above median
Number of subjects: 4300
Study 12628948 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NE above median
Number of subjects: 4300
Study 12628948 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP quartiles
Number of subjects: 4300
Study 12628948 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent decrease in BNP from baseline to 4 and 12 months
Number of subjects: 4300
Study 12628948 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent increase in BNP from baseline to 4 and 12 months
Number of subjects: 4300
Study 12628948 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent decrease in NE from baseline to 4 and 12 months
Number of subjects: 4300
Study 12628948 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent increase in NE from baseline to 4 and 12 months
Number of subjects: 4300
Study 10346073 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential assignment (SA)
Number of subjects: 0
Study 10346073 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 0
Study 7851581 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin acetate for 3 months (n = 20)
Number of subjects: 30
Study 7851581 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 10)
Number of subjects: 30
Study 1659239 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine isethionate intravenously three times each week until parasitological cure
Number of subjects: 312
Study 1659239 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine concomitantly with a 20-day regimen of sodium stibogluconate
Number of subjects: 312
Study 1659239 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine injections followed by 20 days of sodium stibogluconate therapy
Number of subjects: 312
Study 1659239 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine (5 additional injections) followed by a course of antimony therapy
Number of subjects: 312
Study 1659239 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine
Number of subjects: 312
Study 6797298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 10
Study 6797298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg
Number of subjects: 10
Study 6797298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg + Oxyphenonium bromide 10 mg
Number of subjects: 10
Study 6797298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31842950 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetramethylpyrazine (TMP) 100 mg orally three times a day for 16 weeks
Number of subjects: 120
Study 31842950 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 120
Study 29216898 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise
Number of subjects: 100
Study 29216898 — intervention group
Group type: COMPARATOR
Intervention: Quadriceps strengthening exercise
Number of subjects: 100
Study 29216898 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee flexor strength
Number of subjects: 100
Study 26175552 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel preparation (BP)
Number of subjects: 78
Study 26175552 — intervention group
Group type: COMPARATOR
Intervention: Non-bowel preparation (NP)
Number of subjects: 78
Study 24345167 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental dyscalculia
Number of subjects: 0
Study 24345167 — intervention group
Group type: COMPARATOR
Intervention: Numerically normal adults
Number of subjects: 0
Study 24345167 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray matter volume in right TPJ
Number of subjects: 0
Study 24345167 — intervention group
Group type: EXPERIMENTAL
Intervention: Number proficiency
Number of subjects: 0
Study 22863310 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis patients with diabetes
Number of subjects: 301
Study 22863310 — intervention group
Group type: COMPARATOR
Intervention: Diabetes in dialysis patients
Number of subjects: 301
Study 22863310 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental aspects of HRQOL in diabetic patients receiving dialysis
Number of subjects: 301
Study 19574177 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 44
Study 19574177 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture (control)
Number of subjects: 44
Study 17539711 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus chlorhexidine chips
Number of subjects: 26
Study 17539711 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 26
Study 15096808 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 0
Study 15096808 — intervention group
Group type: COMPARATOR
Intervention: Not breastfeeding (Control)
Number of subjects: 0
Study 11479153 — intervention group
Group type: COMPARATOR
Intervention: Biliary atresia
Number of subjects: 86
Study 11479153 — intervention group
Group type: COMPARATOR
Intervention: Fulminant hepatitis
Number of subjects: 86
Study 11479153 — intervention group
Group type: COMPARATOR
Intervention: Neonatal hepatitis
Number of subjects: 86
Study 11479153 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma HGF levels
Number of subjects: 86
Study 11479153 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma TGF-beta1 levels
Number of subjects: 86
Study 11479153 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma HGF-TGF-beta1 ratio
Number of subjects: 86
Study 9504599 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3.0 mg nightly for 30 days
Number of subjects: 30
Study 9504599 — intervention group
Group type: COMPARATOR
Intervention: Placebo nightly for 30 days
Number of subjects: 30
Study 9504599 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin for patients with bilateral tinnitus
Number of subjects: 30
Study 7527674 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmanipulated marrow transplant from HLA-identical siblings
Number of subjects: 58
Study 2646872 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-DTPA (0.1 mmol/kg)
Number of subjects: 88
Study 2646872 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 88
Study 1239216 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine and saline solution
Number of subjects: 18
Study 1239216 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine and LMW dextran 40
Number of subjects: 18
Study 1239216 — intervention group
Group type: COMPARATOR
Intervention: Saline and LMW dextran 40
Number of subjects: 18
Study 31188080 — intervention group
Group type: EXPERIMENTAL
Intervention: High fruit and vegetable intake (≥ 4.9 servings/day)
Number of subjects: 1026
Study 31188080 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of fruit intake
Number of subjects: 1026
Study 31188080 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of vegetable intake
Number of subjects: 1026
Study 31188080 — intervention group
Group type: COMPARATOR
Intervention: Dairy products intake
Number of subjects: 1026
Study 28358546 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance feedback intervention
Number of subjects: 228
Study 25753873 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Duo positive airway pressure (DuoPAP)
Number of subjects: 85
Study 25753873 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (nCPAP)
Number of subjects: 85
Study 23492965 — intervention group
Group type: EXPERIMENTAL
Intervention: VeinViewer
Number of subjects: 600
Study 23492965 — intervention group
Group type: COMPARATOR
Intervention: Routine cannulation
Number of subjects: 600
Study 21639660 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-tape role induction (RI)
Number of subjects: 68
Study 21639660 — intervention group
Group type: COMPARATOR
Intervention: No videotape treatment-as-usual
Number of subjects: 68
Study 18048452 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (alpha-adrenoceptor inhibition)
Number of subjects: 14
Study 18048452 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 14
Study 18048452 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined phentolamine/propranolol (alpha- and beta-adrenoceptor inhibition)
Number of subjects: 14
Study 15644460 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity leg extension exercise (6 sets of 8 repetitions at 80% of 1-RM)
Number of subjects: 12
Study 12876237 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone 200 mg with each daily levodopa dose
Number of subjects: 300
Study 12876237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 10378705 — intervention group
Group type: EXPERIMENTAL
Intervention: Education group (4-week education program, 2 hours per week)
Number of subjects: 77
Study 10378705 — intervention group
Group type: EXPERIMENTAL
Intervention: Education group
Number of subjects: 77
Study 10378705 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 8712328 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.0625% bupivacaine with either 2.5 micrograms.ml‐1 fentanyl or 0.25 micrograms.ml‐1 sufentanil
Number of subjects: 399
Study 8712328 — intervention group
Group type: COMPARATOR
Intervention: 0.125% plain bupivacaine
Number of subjects: 399
Study 1521397 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic toothbrush
Number of subjects: 26
Study 1521397 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothbrush (conventional toothbrush)
Number of subjects: 26
Study 6387717 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 19
Study 6387717 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 19
Study 6387717 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal and Naproxen
Number of subjects: 19
Study 30821716 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained nicorandil administration (5 mg, three times daily)
Number of subjects: 117
Study 30821716 — intervention group
Group type: COMPARATOR
Intervention: Single nicorandil administration before PCI (control group)
Number of subjects: 117
Study 30821716 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained nicorandil administration
Number of subjects: 117
Study 29712593 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Heller myotomy with partial fundoplication
Number of subjects: 0
Study 29712593 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Heller myotomy with partial anterior fundoplication
Number of subjects: 0
Study 29712593 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Heller myotomy with partial posterior fundoplication
Number of subjects: 0
Study 27037483 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit Reversal Training (HRT) group sessions
Number of subjects: 33
Study 27037483 — intervention group
Group type: COMPARATOR
Intervention: Education group sessions
Number of subjects: 33
Study 23435555 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-incentivizing implementation intention condition
Number of subjects: 238
Study 23435555 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard implementation intention condition
Number of subjects: 238
Study 23435555 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 238
Study 21864866 — intervention group
Group type: EXPERIMENTAL
Intervention: HTG clamp
Number of subjects: 10
Study 21864866 — intervention group
Group type: EXPERIMENTAL
Intervention: HTG/IG clamp
Number of subjects: 10
Study 21864866 — intervention group
Group type: COMPARATOR
Intervention: Insulin and glucose administration
Number of subjects: 10
Study 20550712 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 minutes of moderate-intensity aerobic and resistance training, five days per week for 24 weeks
Number of subjects: 80
Study 20550712 — intervention group
Group type: COMPARATOR
Intervention: 45 minutes of stretching, five days per week for 24 weeks
Number of subjects: 80
Study 18094378 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg once daily
Number of subjects: 1370
Study 18094378 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 100 mg once daily
Number of subjects: 1370
Study 14579089 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 degrees data collection
Number of subjects: 30
Study 14579089 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 degrees data collection
Number of subjects: 30
Study 10960219 — intervention group
Group type: EXPERIMENTAL
Intervention: Acts of violence perpetration (self-reported)
Number of subjects: 349
Study 10960219 — intervention group
Group type: EXPERIMENTAL
Intervention: Victimization and witnessing of violent events
Number of subjects: 349
Study 10960219 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual risk behaviors and victimization
Number of subjects: 349
Study 10960219 — intervention group
Group type: EXPERIMENTAL
Intervention: Acts of perpetration
Number of subjects: 349
Study 9108976 — intervention group
Group type: EXPERIMENTAL
Intervention: Worn Polymacon lenses (unwashed)
Number of subjects: 0
Study 9108976 — intervention group
Group type: EXPERIMENTAL
Intervention: Washed worn lenses of both types
Number of subjects: 0
Study 9108976 — intervention group
Group type: COMPARATOR
Intervention: Unworn lenses (controls)
Number of subjects: 0
Study 8264339 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (n-3 PUFA)
Number of subjects: 0
Study 8264339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3915155 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose 250 mg mefloquine
Number of subjects: 46
Study 3915155 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose 500 mg mefloquine
Number of subjects: 46
Study 3915155 — intervention group
Group type: COMPARATOR
Intervention: Standard 3-day treatment with 1,500 mg chloroquine
Number of subjects: 46
Study 30865324 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong Hearts, Healthy Communities (SHHC) intervention; met 1 hour twice a week for 24 weeks, involving aerobic exercise and progressive strength training.
Number of subjects: 192
Study 30865324 — intervention group
Group type: COMPARATOR
Intervention: Control program; met 1 hour each month for 6 months, covering dietary and physical activity recommendations.
Number of subjects: 192
Study 29337405 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 84
Study 29337405 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 84
Study 29337405 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 84
Study 27116510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injections
Number of subjects: 90
Study 27116510 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype analysis of rs699947, rs2010963, and rs3025039 SNPs
Number of subjects: 90
Study 24255160 — intervention group
Group type: COMPARATOR
Intervention: Visual estimation of height
Number of subjects: 100
Study 24255160 — intervention group
Group type: COMPARATOR
Intervention: Tape measure height measurement
Number of subjects: 100
Study 24255160 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower leg measurements
Number of subjects: 100
Study 24255160 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm measurements
Number of subjects: 100
Study 24255160 — intervention group
Group type: COMPARATOR
Intervention: Reference method (height gauge while standing)
Number of subjects: 100
Study 22933669 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-specific NexGen LPS High-Flex prosthesis
Number of subjects: 100
Study 22933669 — intervention group
Group type: COMPARATOR
Intervention: Standard NexGen LPS prosthesis
Number of subjects: 100
Study 20929110 — intervention group
Group type: EXPERIMENTAL
Intervention: HTK solution (nonflushed)
Number of subjects: 89
Study 20929110 — intervention group
Group type: EXPERIMENTAL
Intervention: HTK solution (flushed)
Number of subjects: 89
Study 20929110 — intervention group
Group type: COMPARATOR
Intervention: University of Wisconsin (UW) solution
Number of subjects: 89
Study 18418230 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (group 1, n=40)
Number of subjects: 60
Study 18418230 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal (group 3, n=20)
Number of subjects: 60
Study 18418230 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2, n=20, no high-fat meal)
Number of subjects: 60
Study 15661405 — intervention group
Group type: EXPERIMENTAL
Intervention: Purging with 25 mug/mL ET‐18‐OCH3 combined with cryopreservation at 10% DMSO and hyperthermia at 42 degrees C combined with cryopreservation at 10% or 4% DMSO
Number of subjects: 54
Study 15661405 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal residual disease (MRD) levels
Number of subjects: 54
Study 15661405 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD levels categorized
Number of subjects: 54
Study 15661405 — intervention group
Group type: EXPERIMENTAL
Intervention: Log tumor reduction needed to achieve MRD cut-off of 0.05%
Number of subjects: 54
Study 12232643 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg cisatracurium (Cis 6 group: pretreatment interval 6 min)
Number of subjects: 60
Study 12232643 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg cisatracurium (Cis 3 group: pretreatment interval 3 min)
Number of subjects: 60
Study 12232643 — intervention group
Group type: COMPARATOR
Intervention: Normal saline i.v. (Placebo group)
Number of subjects: 60
Study 10705622 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term hormone replacement therapy (< 10 months)
Number of subjects: 216
Study 10705622 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term hormone replacement therapy (> 11 months)
Number of subjects: 216
Study 10705622 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonusers)
Number of subjects: 216
Study 8758316 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MAC enflurane
Number of subjects: 18
Study 8758316 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MAC isoflurane
Number of subjects: 18
Study 8758316 — intervention group
Group type: COMPARATOR
Intervention: Control group (thiopental and 67% N2O‐O2)
Number of subjects: 18
Study 1746257 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml normal saline solution
Number of subjects: 125
Study 1746257 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml normal saline solution
Number of subjects: 125
Study 1746257 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml normal saline solution
Number of subjects: 125
Study 1746257 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 10 units in 20 ml saline solution
Number of subjects: 125
Study 1746257 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 10 units in 40 ml saline solution
Number of subjects: 125
Study 7064040 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of lignocaine
Number of subjects: 41
Study 31367893 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy + Balneotherapy (PT + BT)
Number of subjects: 305
Study 31367893 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy alone (PT)
Number of subjects: 305
Study 28805022 — intervention group
Group type: EXPERIMENTAL
Intervention: Hesperidin 500 mg/day for 6 weeks
Number of subjects: 64
Study 25528759 — intervention group
Group type: EXPERIMENTAL
Intervention: Going outside into a busy local shopping street
Number of subjects: 59
Study 25528759 — intervention group
Group type: COMPARATOR
Intervention: Staying inside (neutral task indoors)
Number of subjects: 59
Study 25622744 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine preconditioning (Pre-Dex group) - intravenous infusion at a dose of 0.125 ml/kg (4 µg/ml) for 10 minutes before tourniquet use.
Number of subjects: 60
Study 25622744 — intervention group
Group type: COMPARATOR
Intervention: Control group (R group) - conventional general anesthesia, received normal saline equivalent to dexmedetomidine volume.
Number of subjects: 60
Study 22269229 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Cavity Shield) applied three times during one week (once every 2 days)
Number of subjects: 250